Profile data is unavailable for this security.
About the company
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
- Revenue in USD (TTM)58.88m
- Net income in USD-32.18m
- Incorporated2007
- Employees142.00
- LocationAlpine Immune Sciences Inc188 East Blaine St., Suite 200SEATTLE 98102United StatesUSA
- Phone+1 (206) 788-4545
- Fax+1 (302) 636-5454
- Websitehttps://www.alpineimmunesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.49bn | 557.00 | -- | 5.48 | -- | 2,936.37 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Biohaven Ltd | 0.00 | -408.17m | 3.55bn | 239.00 | -- | 7.62 | -- | -- | -5.67 | -5.67 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -69.48 | -- | -79.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 4.01m | -214.53m | 3.55bn | 290.00 | -- | 5.70 | -- | 883.99 | -3.70 | -3.70 | 0.0691 | 7.91 | 0.0081 | -- | 0.7048 | 13,837.93 | -42.39 | -42.53 | -45.71 | -45.36 | -- | -- | -5,216.32 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Axsome Therapeutics Inc | 270.60m | -239.24m | 3.55bn | 545.00 | -- | 18.57 | -- | 13.11 | -5.20 | -5.20 | 5.96 | 4.03 | 0.5885 | 2.68 | 4.08 | 496,513.80 | -52.02 | -64.55 | -69.92 | -82.23 | 90.37 | -- | -88.41 | -227.05 | 3.52 | -35.93 | 0.4825 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Ultragenyx Pharmaceutical Inc | 434.25m | -606.64m | 3.57bn | 1.28k | -- | 12.94 | -- | 8.21 | -8.33 | -8.33 | 5.91 | 3.35 | 0.286 | 1.49 | 7.63 | 340,320.50 | -39.96 | -33.35 | -48.63 | -38.30 | 89.59 | 93.13 | -139.70 | -154.71 | 2.49 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.67bn | 271.00 | 26.39 | 2.23 | 22.70 | 2.90 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Insmed Inc | 305.21m | -749.57m | 3.80bn | 912.00 | -- | -- | -- | 12.46 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Alvotech SA | 93.38m | -551.73m | 3.86bn | 999.00 | -- | -- | -- | 41.37 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Alkermes Plc | 1.73bn | 599.95m | 4.06bn | 2.10k | 6.86 | 3.24 | 6.12 | 2.35 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Immunovant Inc | 0.00 | -243.45m | 4.14bn | 164.00 | -- | 6.09 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
| Alpine Immune Sciences Inc | 58.88m | -32.18m | 4.23bn | 142.00 | -- | 11.89 | -- | 71.92 | -0.6827 | -0.6827 | 1.18 | 5.43 | 0.1767 | -- | 210.65 | 414,619.70 | -9.66 | -21.93 | -11.36 | -27.81 | -- | -- | -54.66 | -170.16 | -- | -- | 0.00 | -- | 95.84 | 142.30 | 44.28 | -- | -0.3253 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 4.48bn | 376.00 | -- | 10.33 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Krystal Biotech Inc | 50.70m | 10.93m | 4.55bn | 229.00 | 1,804.39 | 5.79 | 269.88 | 89.80 | 0.0885 | 0.0885 | 1.84 | 27.58 | 0.0737 | -- | -- | 221,393.00 | 1.59 | -11.50 | 1.66 | -12.01 | 93.90 | -- | 21.56 | -492.85 | 17.55 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Nuvalent Inc | 0.00 | -126.22m | 4.56bn | 92.00 | -- | 6.46 | -- | -- | -2.16 | -2.16 | 0.00 | 10.94 | 0.00 | -- | -- | 0.00 | -20.78 | -- | -21.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Organon & Co | 6.26bn | 1.02bn | 4.81bn | 10.00k | 4.72 | -- | 3.82 | 0.7686 | 3.99 | 3.99 | 24.44 | -0.2738 | 0.5443 | 2.17 | 3.89 | 626,300.00 | 8.89 | 16.53 | 11.64 | 20.97 | 59.84 | 65.12 | 16.33 | 26.79 | 1.09 | 2.31 | 1.01 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
Data as of May 02 2024. Currency figures normalised to Alpine Immune Sciences Inc's reporting currency: US Dollar USD
42.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2023 | 4.91m | 7.49% |
| Lynx1 Capital Management LPas of 31 Dec 2023 | 3.81m | 5.82% |
| Great Point Partners LLCas of 31 Dec 2023 | 3.70m | 5.65% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 3.18m | 4.85% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.75m | 4.20% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 2.55m | 3.89% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.16m | 3.29% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.66m | 2.54% |
| Commodore Capital LPas of 31 Dec 2023 | 1.61m | 2.46% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.39m | 2.12% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
